A phase II study on sequential combination therapy comprising CDDP+VNR+MMC combination chemotherapy followed by concomitant-boost thoracic radiotherapy with daily CDDP in advanced non-small cell lung cancer (LA-NSCLC)

7294 Background: While the prognosis for LA-NSCLC has improved, satisfactory results have not been obtained. Therapeutic outcomes for radiotherapy combined with low-dose of CDDP were significantly better than radiotherapy alone. We conducted a phase II study of combination chemotherapy with CDDP, VNR, and MMC followed by concomitant-boost radiotherapy with daily CDDP. Methods: This study was a multicenter phase II trial. The primary endpoint was...